These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.

Continuing high prices and demand for GLP-1 weight-loss drugs is creating lots of questions about the affordability of these drugs for U.S. healthcare consumers. For more than two years ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

U.S. weight-loss drug prices exceed those in other developed countries Drugmakers say they support fairer cost-sharing across countries Some 40% of Americans estimated to have obesity Executive ...

The Danish drugmaker Novo Nordisk announced it has temporarily reduced the price of the weight-loss drug Wegovy for new customers as it attempts to limit sales of compounded versions of the ...

Weight-loss drugs are already dropping in price; could they go even lower? - Consumers are now able to pay roughly $500 for ...

The price of weight loss drugs is falling. Wegovy and Zepbound, which both sell for a list price of more than $1,000 a month, have long been out of reach for people without insurance or whose ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

Injected weight-loss drugs Wegovy, from Novo Nordisk, and Eli Lilly's Zepbound have U.S. list prices of over $1,000 a month. For some patients, much of that cost is covered by health insurance.

Cigna Group’s drug ... expensive weight-loss drugs that it says will make the medicines available to more patients. Under the new option, patients would pay less than the cash price for Eli ...